A clinical trial to determine if the investigational MnB vaccine works the same every time a batch (or lot) of the vaccine is made

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-023873-20

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Co-Primary  To demonstrate that the immune response induced by 3 lots of rLP2086 vaccine are equivalent as measured by serum bactericidal assay using human complement (hSBA) performed with MnB strains expressing LP2086 subfamily A and B proteins, 1 month after study vaccination 3.  To assess the immune response as measured by serum bactericidal assay using human complement (hSBA) performed with MnB strains expressing LP2086 subfamily A and B proteins, measured 1 month after study vaccination 3 in a subset of subjects in group 1. Primary Safety  To evaluate the safety profile of 3 lots of rLP2086 vaccine as measured by the proportion of subjects reporting local reactions, systemic events and adverse events (AEs).


Critère d'inclusion

  • bacterial meningitis